Ontology highlight
ABSTRACT:
SUBMITTER: Yang S
PROVIDER: S-EPMC6498593 | biostudies-literature | 2019 May
REPOSITORIES: biostudies-literature
Yang Sen S Zhang Zhe Z Wang Qiming Q
Journal of hematology & oncology 20190502 1
Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembrolizumab, atezolizumab, and durvalumab have led to significant improvements in clinical outcomes of SCLC. Regarding options in other classes of therapy, the cytotoxic drug lurbinectedin was granted orphan drug status based on a remarkable objective response rate of 39.3%. In addition, an increa ...[more]